GlassScriptPhysician profile
Laura C Williams
NPI 1548330202
$5,851.39
in general payments reported to CMS, 2019-2025
28 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $456 · 2021: $495 · 2022: $664 · 2023: $1,135 · 2024: $1,079 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,596.33 |
| Education | $193.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,392.96 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Lilly USA, LLC | $775.59 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $664.26 | 2019-2025 | |
| Janssen Biotech, INC. | $565.13 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $396.27 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $385.98 | 2019-2025 | |
| Leo Pharma INC. | $337.35 | 2021-2025 | Adbry |
| Ucb, INC. | $240.23 | 2020-2024 | Bimzelx, Cimzia |
| Amgen INC. | $211.66 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $145.11 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $137.13 | 2020-2024 | Winlevi, Absorica Ld |
| Incyte Corporation | $130.89 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $124.80 | 2022-2025 | Nemluvio, Aklief |
| Kerecis Limited | $55.79 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Dermavant Sciences, INC. | $42.35 | 2023 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $37.92 | 2019 | |
| Pfizer INC. | $24.53 | 2019 | |
| Lnhc, INC | $24.53 | 2025 | Zelsuvmi |
| Krystal Biotech INC | $20.69 | 2023 | Vyjuvek |
| Mallinckrodt Hospital Products INC. | $20.31 | 2024 | Acthar |
| Arcutis Biotherapeutics, INC. | $20.20 | 2025 | Zoryve |
| Genentech USA, INC. | $18.72 | 2020 | |
| Botanix Sb INC | $17.40 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $16.20 | 2023 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.48 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $13.46 | 2019 | |
| Celgene Corporation | $12.08 | 2019 | |
| Organon LLC | $4.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.